Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals reported its Q2 2025 earnings on August 7, 2025, with an EPS of -$0.100 USD. The company held its Annual General Meeting on June 12, 2025. On May 8, 2025, it released its Q1 2025 earnings, reporting an EPS of -$0.130 USD. Q4 2024 earnings were reported on March 25, 2025, with an EPS of -$0.160 USD. Corvus Pharmaceuticals announced the presentation of interim data from the Phase 1b/2 clinical trial of ciforadenant at the ESMO Congress 2025 on October 17, 2025. David Moore was appointed to the Board of Directors on October 2, 2025. Barclays initiated coverage of Corvus Pharmaceuticals with an "Overweight" rating and a $16 price target in October 2025. In December 2024, the stock plummeted approximately 40% after Phase 1 data for soquelitinib in atopic dermatitis showed mixed results.

As a clinical-stage biopharmaceutical company without commercial products generating revenue, the concept of demand seasonality is not applicable to Corvus Pharmaceuticals at this stage. Its value is currently derived from its development pipeline and the successful advancement of its drug candidates through clinical trials.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing novel immuno-oncology therapies. The company targets proteins critical to immune cell maturation and function, aiming to harness both the innate and adaptive immune systems to combat tumor-driven immunosuppression. Its major product candidates include Soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK) in Phase 1/1b clinical trial; Ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor in Phase 2 clinical trial; and Mupadolimab (CPI-006), a humanized monoclonal antibody targeting CD73 in Phase 1b clinical trial. The company's pipeline also includes other immune modulator product candidates such as B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.

Corvus Pharmaceuticals, Inc. is headquartered in South San Francisco, California, United States. The company has a strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab, indicating an international reach for its clinical programs. Corvus also aims to establish partnerships and collaborations to bring its therapies to patients worldwide, supporting a strategy of generating robust clinical data and exploring combination regimens for high-unmet-need cancers.

In the past year, Corvus Pharmaceuticals' brand reputation has been influenced by both positive and challenging events. The company has received a consensus rating of "Moderate Buy" or "Strong Buy" from analysts, with an average price target suggesting significant upside potential. However, the stock price dropped significantly (around 40%) in December 2024 following the announcement of mixed Phase 1 data for soquelitinib in atopic dermatitis, raising questions about the reliability of the results. Despite this setback, the company continues to advance its clinical programs and engage in strategic collaborations.

As of late 2024, 46.64% of Corvus Pharmaceuticals' stock is held by institutions, and insiders hold 28.50% of the stock. Top institutional shareholders include Masso Torrence Wealth Management Inc. and Shelton Wealth Management LLC. Individual insiders who own company stock include Peter A. Thompson, Richard A. Miller, William Benton Jones, Leiv Lea, and Linda Grais.